New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 12, 2013
16:20 EDTVOD, ULTA, CTB, BIIB, LYV, HMA, GTOn The Fly: Closing Wrap
Stocks on Wall Street were lower despite opening sharply higher as the market looked to avoid its first three day losing streak of the year. Downside momentum quickly took hold however, and the averages moved steadily lower through the session, moving to their lows in the final hour of trading but finishing just off those levels. ECONOMIC EVENTS: In the U.S., the MBA's purchase applications composite index rose 5.0% for the week. The U.S. posted a $139B May budget deficit against expectations for a $130B deficit, and compared to a $124.6B deficit a year ago. In Europe, factory production in the 17-nation euro area rose 0.4% in April from March, compared to expectations for it to remain unchanged. COMPANY NEWS: Cooper Tire (CTB) agreed to be acquired by India's Apollo Tyres for $35.00 per share in cash, or $2.5B. Cooper shares surged $10.10, or 41.12%, to $34.66 to trade near $34.50 following the deal announcement, while peer Goodyear Tire (GT) advanced about 33c, or 2.26%, to $14.93... Live Nation (LYV) shares gained $2.33, or 16.84%, to $16.17 after the company announced it prevailed in an arbitration ruling related to a ticketing license software agreement... MAJOR MOVERS: Among the notable gainers was Ulta Salon (ULTA), up $12.51, or 14.87%, to $96.64 following its quarterly earnings report. Also higher was Health Management (HMA), up $1.58, or 11.34%, to $15.51 after Glenview Capital said in a filing it is seeking to repeal a provision that prevents entities from holding more than 15% of the company's stock and saying it would look to nominate candidates to the company's board. Among noteworthy losers was Biogen (BIIB), down $16.48, or 7.39%, to $206.55 after the stock was downgraded to Neutral from Buy at Citigroup, which cited concerns that EU medical regulators are unlikely to approve the company's multiple sclerosis treatment. Also lower were U.S.-listed shares of Vodafone (VOD), down 71c, or 2.47%, to $28.12 after the company confirmed it approached Kabel Deutschland about a possible deal. INDICES: The Dow was down 126.79, or 0.84%, to 14,995.23; the S&P 500 was down 13.61, or 0.84%, to 1,612.52; the Nasdaq was down 36.52, or 1.06%, to 3,400.43.
News For CTB;GT;LYV;ULTA;HMA;BIIB;VOD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
July 24, 2015
06:50 EDTBIIBBiogen reports Q2 non-GAAP EPS $4.22, consensus $4.10
Subscribe for More Information
05:32 EDTVODVodafone backs FY16 outlook
Subscribe for More Information
05:31 EDTVODVodafone reports Q1 Group revenue GBP 10.11B
Reports Q3 service revenue GBP 9.17B, down 0.9% on a reported basis and up 3.3% on an organic basis. Reports continued recovery in Europe: Germany -1.2%*, UK 0.2%*, Italy -2.0%*, Spain -5.5%. CEO Vittorio Colao commented, ". Our emerging markets have maintained their strong momentum and more of our European businesses are returning to growth, as customer demand for 4G and data takes off. We continue to hit our Project Spring build milestones and customers are beginning to value the improvement in service that is resulting: contract churn in Europe is now falling and mobile ARPU trends are stabilising in a number of key markets."
July 23, 2015
15:05 EDTBIIBNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's open, with earnings consensus, include AbbVie (ABBV), consensus $1.06... Biogen (BIIB), consensus $4.10... Simon Property Group (SPG), consensus $2.36... State Street (STT), consensus $1.37... V.F. Corp. (VFC), consensus 36c... Johnson Controls (JCI), consensus 91c... American Airlines (AAL), consensus $2.60... Rockwell Collins (COL), consensus $1.30... Cabot Oil & Gas (COG), consensus 4c... Lear (LEA), consensus $2.48... Encana (ECA), consensus (15c).
13:42 EDTBIIBBiogen technical remarks ahead of earnings
Subscribe for More Information
08:03 EDTBIIBBiogen update 'promising,' says RBC Capital
RBC Capital says that there were negative aspects to yesterday's update on the trial results of Biogen's Alzheimer's treatment. Specifically, the 6 mg version of the drug only slightly improved patients' performance on one cognition test compared with the most recently chosen group of ten patients taking placebos, and did not improve their performance at all on another cognition test. However, RBC says that the drug did improve patients' performance on both tests versus the 20+ patients who were in a previous placebo group. Additionally, the firm reports that the cognition test on which the patients taking the drug outperformed versus the newer placebo group is more widely accepted than the other cognition test. RBC sees a 50%-60% chance that the drug will succeed.
07:00 EDTBIIBBiogen July weekly volatility elevated into Q2 and outlook
Biogen July weekly call option implied volatility is at 77, August is at 37, September is at 34; compared to its 52-week range of 23 to 46, suggesting large near term price movement into the expected release of Q2 results on July 24.
July 22, 2015
10:59 EDTBIIBBiogen drops after reporting data on Alzheimer's drug
The shares of Biogen (BIIB) are falling after the company released data on its Alzheimer's treatment candidate, aducanumab. Peer Eli Lilly (LLY) also reported data this morning on its own experimental Alzheimer's drug, solanezumab. BIOGEN: Biogen's data "does not inspire confidence," Piper analyst Joshua Schimmer wrote in a note to investors today. The 6 mg dose of the drug performed similarly to the 1mg dose, and was barely better than the placebo, the analyst stated. The cognitive and functional performance of the patients who took the 6 mg dose did not improve by a statistically significant amount, while the results of patients taking the other doses were "noisy,"Schimmer stated. Additionally, indications of excess fluid in the brain was observed in a significant number of patients, representing an additional problem for the treatment, the analyst believes. The data "is far from inspiring confidence" and makes the outlook for aducanumab "more speculative than ever," Schimmer contended. LILLY: Also this morning, Eli Lilly presented results from a pre-specified secondary analysis of several Phase 3 studies at the Alzheimer's Association International Conference. According to the company, the results suggest the treatment effect of solanezumab was preserved within a pre-specified amount in patients with mild Alzheimer's disease who received solanezumab earlier in the disease compared to patients who began treatment at a later point. Treatment differences in cognition and function between early-start and delayed-start groups at the end of the placebo-controlled period were preserved at the primary time point of 108 weeks within a pre-defined margin. Treatment differences in cognition and function between early-start and delayed-start groups at the end of the placebo-controlled period were also preserved at an additional time point of 132 weeks within a pre-defined margin.The differences at 108 weeks and at at 132 weeks remained statistically significant, the company said. PRICE ACTION: In morning trading, Biogen fell 3% to $397.43 while Eli Lilly shares rose 0.6% to $86.11.
10:01 EDTBIIBOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:28 EDTBIIBBiogen downgraded to Neutral at Piper Jaffray after Alzheimer's data
Subscribe for More Information
09:22 EDTBIIBBiogen downgraded to Neutral from Overweight at Piper Jaffray
Subscribe for More Information
09:07 EDTBIIBOn The Fly: Pre-market Movers
Subscribe for More Information
07:19 EDTBIIBBiogen drops 4.8% to $390 after reporting Alzheimer's drug data
06:50 EDTBIIBBiogen's Alzheimer's candidate shows reduction of clinical decline
Subscribe for More Information
July 21, 2015
07:30 EDTULTAUlta Salon price target raised to $180 from $173 at JPMorgan
Subscribe for More Information
06:24 EDTBIIBPiper expects 'stronger, bolder' move from Biogen
Subscribe for More Information
06:12 EDTBIIBBiogen implied volatility of 50 at upper end of index
July 20, 2015
14:22 EDTVODEarnings Watch: Verizon to report Q2 results after AOL acquisition
Verizon Communications (VZ) is expected to report second quarter earnings before the market open on Tuesday, July 21, with a conference call scheduled for 8:30 am ET. Verizon is a holding company providing communications, information and entertainment. EXPECTATIONS: Analysts are looking for earnings per share of $1.01 on revenue of $32.45B, according to First Call. The consensus range for EPS is 93c-$1.05 on revenue of $31.75B-$33.0B. LAST QUARTER: Verizon reported first quarter EPS of $1.02 against estimates for 95c on revenue of $32B against estimates for $32.27B. Verizon Wireless had 565,000 retail postpaid net additions in Q1, a 4.8% increase compared with first-quarter 2014. At the end of Q1, the company had 108.6M retail connections, a 5.1% year-over-year increase, and had 102.6M retail postpaid connections. The company added 621,000 4G smartphones to its customer base in Q1. In light of a net decline in 3G smartphones, overall smartphone growth totaled 247,000. The company also added 820,000 4G tablets and reported net declines of 385,000 basic phones and 188,000 prepaid devices in Q1. 4G devices now constitute approximately 70% of the retail postpaid connections base, up from 49% a year ago – with the 4G LTE network handling about 86% of total wireless data traffic in Q1. At 1.03% in Q1, retail postpaid churn improved both sequentially and year over year. Retail postpaid smartphone customer churn was less than 0.9%. Verizon added 133K net new FiOS Internet, and 90K net new FiOS Video connections in Q1. Verizon had totals of 6.7M FiOS Internet and 5.7M FiOS Video connections at the end of the first quarter, representing year-over-year increases of 9.4% and 7.9%, respectively. CEO Lowell McAdam said, “We are confident in our ability to maintain momentum and continue to add value for customers and shareholders.” On May 12, Verizon announced it would acquire AOL for $50 per share, or $4.4B. The transaction was completed on June 23. On May 19, speaking at the JPMorgan Global Technology, Media and Telecom Conference, CFO Fran Shammo said he expects net phone additions in Q2. ANALYST REACTION: Street research has been mostly mixed in the weeks leading up to Verizon’s Q2 earnings report. On May 12, Macquarie downgraded Verizon to Underperform from Neutral with a $45 price target to reflect a weaker 2016 and 2017 earnings outlook. The firm's analyst believed management has made a series of questionable strategic moves beginning with the Vodafone (VOD) deal that will depress earnings. Recent advertising promotions are likely to pressure 2015 margins and ARPU and LTE capacity issues are expected in certain markets later in the year. Macquarie is surprised Verizon shares have held in around $50 with treasury yields rising and increasing Q2 promotions and does not believe this is sustainable ahead of a reset in consensus estimates. Conversely, on July 9, Stifel resumed coverage of Verizon with a Buy rating and price target of $60 per share. PRICE ACTION: Verizon’s shares are down about 3% since the company's Q1 report. Over the past twelve months, they are down about 5.7%. In afternoon trading ahead of Tuesday's Q2 report, Verizon’s shares are up 0.6%.
07:41 EDTVODBT CEO: Company split doesn't solve problems, Telegraph reports
Subscribe for More Information
07:32 EDTBIIBAlzheimer's Association to hold a conference
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use